Middle East Pharmaceutical Industries Company (4016) Fair Value & Analysis

Healthcare · SA · Market cap 2.0B SAR

What matters now

• Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (31.90 SAR to 72.77 SAR) leaves room in how you read the outcome.

Price vs Fair Value (12 months)

12‑month range 54.24 SAR – 10,642 SAR · fair‑value band 31.90 SAR – 72.77 SAR · the 57.80 SAR price screens above the 46.83 SAR fair value. As of Jul 31, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Middle East Pharmaceutical Industries Company (4016) currently trades at 57.80 SAR, while our model-based Fair Value estimate is 46.83 SAR, implying the stock looks roughly 19.0% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Middle East Pharmaceutical Industries Company generated revenue of 493M SAR at a net margin of 21.2%. Revenue grew 33.7% year over year. It earns a return on equity of 26.0%. Net debt stands at 29.5M SAR. Fundamentals as of Jul 31, 2026

Our scenario range runs from 31.90 SAR (bear case) to 72.77 SAR (bull case); at 57.80 SAR, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -19%, 4016 screens cheaper than that median.

Key figures & financial health

Quality Score breakdown

About the company

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export.

Full company description

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS. It exports its products. The company was formerly known as Middle East Chemical Products Factory Company and changed its name to Middle East Pharmaceutical Industries Company in January 2006. Middle East Pharmaceutical Industries Company was incorporated in 1998 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Middle East Pharmaceutical Industries Company reported revenue of 460M SAR in FY2025 versus 287M SAR in FY2021, a compound +12.5%/yr. Reported net income was 97.0M SAR in FY2025, compounding +10.0%/yr from FY2021.

Is 4016 fairly valued? → Check now

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.